Tillotts Pharma

Mage Biologics announces first subject dosed in a phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for the treatment of inflammatory bowel disease (IBD).The trial is a randomised, double-blind, phase 1 study to assess the safety and pharmacokinetics of single and multiple...

Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for the treatment of inflammatory bowel disease (IBD).The trial is a randomised, double-blind phase 1 study to assess the safety and pharmacokinetics of single and multiple...
Baslerstrasse 15 CH-4310 Rheinfelden Switzerland

+41 61 935 26 26